Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone versus indapamide for glycocalyx protection in hypertension
ACTRN12616000933459Phase 2Withdrawn
- Sponsor
- Eastern Health Integrated Renal Service
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of spironolactone and indapamide in hypertension (HTN) (2 arms), sponsored by Eastern Health Integrated Renal Service. Primary endpoints: Change in glycocalyx measured by GlycoCheck, Change in serum syndecan-1 and 1 more. Planned start Jul 2016; status: withdrawn.
02
Drugs
spironolactoneindapamide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ACTRN12616000933459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000933459.